Hubei Cancer Hospital
Wuhan, Hubei, China
71 recruiting
Showing 1–20 of 112 trials
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled364 locationsNCT06890598
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled23 locationsNCT07347600
Recruiting
Phase 2Phase 3
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Gastroesophageal-junction CancerEsophageal AdenocarcinomaMetastatic Gastric Cancer+1 more
Pfizer840 enrolled71 locationsNCT07392892
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled295 locationsNCT06926868
Recruiting
Phase 2Phase 3
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
GIST - Gastrointestinal Stromal TumorAdvanced
Ningbo Newbay Technology Development Co., Ltd255 enrolled32 locationsNCT07379047
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled191 locationsNCT04892173
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled51 locationsNCT07234162
Recruiting
Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines310 enrolled52 locationsNCT06596473
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Advanced Solid TumorSolid Tumor
BeOne Medicines217 enrolled28 locationsNCT05981703
Recruiting
Phase 1
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines525 enrolled87 locationsNCT06589596
Recruiting
Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Daiichi Sankyo540 enrolled232 locationsNCT06203210
Recruiting
Phase 1
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines153 enrolled26 locationsNCT06598800
Recruiting
Phase 3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled71 locationsNCT07165951
Recruiting
Phase 1
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines168 enrolled53 locationsNCT06625593